AVALO THERAPEUTICS INC (AVTX)

US05338F3064 - Common Stock

6.52  -0.35 (-5.09%)

After market: 6.5 -0.02 (-0.31%)

Fundamental Rating

2

Overall AVTX gets a fundamental rating of 2 out of 10. We evaluated AVTX against 572 industry peers in the Biotechnology industry. The financial health of AVTX is average, but there are quite some concerns on its profitability. AVTX does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVTX had negative earnings in the past year.
In the past year AVTX has reported a negative cash flow from operations.
AVTX had negative earnings in each of the past 5 years.
In the past 5 years AVTX always reported negative operating cash flow.

1.2 Ratios

AVTX has a better Return On Assets (-35.87%) than 60.88% of its industry peers.
AVTX's Return On Equity of -155.34% is on the low side compared to the rest of the industry. AVTX is outperformed by 65.49% of its industry peers.
Industry RankSector Rank
ROA -35.87%
ROE -155.34%
ROIC N/A
ROA(3y)-126.77%
ROA(5y)-113.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 191.95%, AVTX belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
AVTX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AVTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 191.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.65%
GM growth 5Y-9.11%

More info and screens

5

2. Health

2.1 Basic Checks

AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVTX has less shares outstanding than it did 1 year ago.
AVTX has less shares outstanding than it did 5 years ago.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

AVTX has an Altman-Z score of -5.13. This is a bad value and indicates that AVTX is not financially healthy and even has some risk of bankruptcy.
AVTX has a Altman-Z score of -5.13. This is in the lower half of the industry: AVTX underperforms 63.01% of its industry peers.
AVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.13
ROIC/WACCN/A
WACC12.08%

2.3 Liquidity

A Current Ratio of 1.42 indicates that AVTX should not have too much problems paying its short term obligations.
The Current ratio of AVTX (1.42) is worse than 82.83% of its industry peers.
AVTX has a Quick Ratio of 1.42. This is a normal value and indicates that AVTX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of AVTX (1.42) is worse than 81.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.42

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 56.16% over the past year.
Looking at the last year, AVTX shows a very negative growth in Revenue. The Revenue has decreased by -63.72% in the last year.
The Revenue for AVTX have been decreasing by -22.83% on average. This is quite bad
EPS 1Y (TTM)56.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.27%
Revenue 1Y (TTM)-63.72%
Revenue growth 3Y-34.03%
Revenue growth 5Y-22.83%
Sales Q2Q%5.51%

3.2 Future

Based on estimates for the next years, AVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.09% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y92.38%
EPS Next 2Y41.07%
EPS Next 3Y25.86%
EPS Next 5Y15.09%
Revenue Next Year-87.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

AVTX's earnings are expected to grow with 25.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.07%
EPS Next 3Y25.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVALO THERAPEUTICS INC

NASDAQ:AVTX (1/14/2025, 8:24:51 PM)

After market: 6.5 -0.02 (-0.31%)

6.52

-0.35 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners39.3%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change0%
Market Cap67.74M
Analysts84
Price Target33.66 (416.26%)
Short Float %0.23%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-54.43%
Min EPS beat(2)-105.88%
Max EPS beat(2)-2.98%
EPS beat(4)0
Avg EPS beat(4)-3499.35%
Min EPS beat(4)-11614.9%
Max EPS beat(4)-2.98%
EPS beat(8)3
Avg EPS beat(8)-1738.06%
EPS beat(12)6
Avg EPS beat(12)-1149.73%
EPS beat(16)7
Avg EPS beat(16)-867.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.71%
PT rev (3m)-5.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-346%
EPS NY rev (1m)0%
EPS NY rev (3m)-369.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.46%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.61
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 5.54
EV/EBITDA N/A
EPS(TTM)-272.53
EYN/A
EPS(NY)-4.79
Fwd EYN/A
FCF(TTM)-3.54
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0.08
BVpS2.19
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.87%
ROE -155.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 191.95%
FCFM N/A
ROA(3y)-126.77%
ROA(5y)-113.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.65%
GM growth 5Y-9.11%
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.44%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.42
Altman-Z -5.13
F-Score3
WACC12.08%
ROIC/WACCN/A
Cap/Depr(3y)55.15%
Cap/Depr(5y)35.08%
Cap/Sales(3y)3.6%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.27%
EPS Next Y92.38%
EPS Next 2Y41.07%
EPS Next 3Y25.86%
EPS Next 5Y15.09%
Revenue 1Y (TTM)-63.72%
Revenue growth 3Y-34.03%
Revenue growth 5Y-22.83%
Sales Q2Q%5.51%
Revenue Next Year-87.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-27.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.84%
OCF growth 3YN/A
OCF growth 5YN/A